Download PDF
Hamostaseologie 2021; 41(01): 069-075
DOI: 10.1055/a-1325-0268
Review Article

Measuring Fibrinolysis

Colin Longstaff 
1   Department of Biotherapeutics, National Institute for Biological Standards and Control, South Mimms, Herts, United Kingdom
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Physiological fibrinolysis under normal conditions progresses slowly, in contrast to coagulation which is triggered rapidly to stop bleeding and defend against microbial invasion. Methods to detect fibrinolysis abnormalities are less simple and poorly standardized compared with common coagulation tests. Fibrinolysis can be accelerated by preparing euglobulin from plasma to reduce endogenous inhibitors, or by adding plasminogen activators to normal plasma. However, these manipulations complicate interpretation of results and diagnosis of a “fibrinolysis deficit.” Many observational studies on antigen levels of fibrinolysis inhibitors, plasminogen activator inhibitor 1 or thrombin-activatable fibrinolysis inhibitor, zymogen or active enzyme have been published. However, conclusions are mixed and there are clear problems with harmonization of results. Viscoelastic methods have the advantage of being rapid and are used as point-of-care tests. They also work with whole blood, allowing the contribution of platelets to be explored. However, there are no agreed protocols for applying viscoelastic methods in acute care for the diagnosis of hyperfibrinolysis or to direct therapy. The emergence of SARS-CoV-2 and the dangers of associated coagulopathy provide new challenges. A common finding in hospitalized patients is high levels of D-dimer fibrin breakdown products, indicative of ongoing fibrinolysis. Well-established problems with D-dimer testing standardization signal that we should be cautious in using results from such tests as prognostic indicators or to target therapies.

Keywords

fibrinolysis - biomarkers - standardization - thrombolytics - antifibrinolytics


Publication History

Received: 28 September 2020

Accepted: 26 November 2020

Article published online:
15 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost 2015; 13 (Suppl. 01) S98-S105
    CrossrefPubMedGoogle Scholar
  • 2 Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7 (01) 4-13
    CrossrefPubMedGoogle Scholar
  • 3 Thelwell C. Fibrinolysis standards: a review of the current status. Biologicals 2010; 38 (04) 437-448
    CrossrefPubMedGoogle Scholar
  • 4 Coxon CH, Longstaff C, Burns C. Applying the science of measurement to biology: Why bother?. PLoS Biol 2019; 17 (06) e3000338
    CrossrefPubMedGoogle Scholar
  • 5 Longstaff C, Whitton CM, Stebbings R, Gray E. How do we assure the quality of biological medicines?. Drug Discov Today 2009; 14 (1–2): 50-55
    CrossrefPubMedGoogle Scholar
  • 6 Huish S, Thelwell C, Longstaff C. Activity regulation by fibrinogen and fibrin of streptokinase from Streptococcus pyogenes. PLoS One 2017; 12 (01) e0170936
    CrossrefPubMedGoogle Scholar
  • 7 Locke M, Rigsby P, Longstaff C. SSC Communication on behalf of the Fibrinolysis Subcommittee. An international collaborative study to establish the WHO 4th International Standard for Streptokinase: communication from the SSC of the ISTH. J Thromb Haemost 2020; 18 (06) 1501-1505
    CrossrefPubMedGoogle Scholar
  • 8 Thelwell C. Biological standards for potency assignment to fibrinolytic agents used in thrombolytic therapy. Semin Thromb Hemost 2014; 40 (02) 205-213
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Beebe DP, Aronson DL. An automated fibrinolytic assay performed in microtiter plates. Thromb Res 1987; 47 (01) 123-128
    CrossrefPubMedGoogle Scholar
  • 10 Longstaff C, Whitton CM. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. J Thromb Haemost 2004; 2 (08) 1416-1421
    CrossrefPubMedGoogle Scholar
  • 11 Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemost 2012; 10 (11) 2354-2360
    CrossrefPubMedGoogle Scholar
  • 12 European Commission. Alteplase for injection. Monograph, European Pharmacopoeia, 2007. European Pharmacopoeia; Strasbourg. 2013: 1170
    Google Scholar
  • 13 Bonnard T, Law LS, Tennant Z, Hagemeyer CE. Development and validation of a high throughput whole blood thrombolysis plate assay. Sci Rep 2017; 7 (01) 2346
    CrossrefPubMedGoogle Scholar
  • 14 Longstaff C. Subcommittee on Fibrinolysis. Development of Shiny app tools to simplify and standardize the analysis of hemostasis assay data: communication from the SSC of the ISTH. J Thromb Haemost 2017; 15 (05) 1044-1046
    CrossrefPubMedGoogle Scholar
  • 15 Rosendaal FR, Reitsma PH. Reproducibility. J Thromb Haemost 2017; 15 (05) 833
    CrossrefPubMedGoogle Scholar
  • 16 Longstaff C. Shiny-Clots. Updated 2019. Accessed November, 2020 at: https://drclongstaff.github.io/shiny-clots/
    PubMedGoogle Scholar
  • 17 Kolev K, Longstaff C. Bleeding related to disturbed fibrinolysis. Br J Haematol 2016; 175 (01) 12-23
    CrossrefPubMedGoogle Scholar
  • 18 Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haemost 2018; 16 (04) 652-662
    CrossrefPubMedGoogle Scholar
  • 19 Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112 (5–6): 329-337
    CrossrefPubMedGoogle Scholar
  • 20 Ilich A, Noubouossie DF, Henderson M. et al. Development and application of global assays of hyper- and hypofibrinolysis. Res Pract Thromb Haemost 2019; 4 (01) 46-53
    CrossrefPubMedGoogle Scholar
  • 21 Pieters M, Philippou H, Undas A, de Lange Z, Rijken DC, Mutch NJ. Subcommittee on Factor XIII and Fibrinogen, and the Subcommittee on Fibrinolysis. An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (05) 1007-1012
    CrossrefPubMedGoogle Scholar
  • 22 Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. Semin Thromb Hemost 2017; 43 (02) 178-184
    PubMedGoogle Scholar
  • 23 van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res 2012; 129 (06) 681-687
    CrossrefPubMedGoogle Scholar
  • 24 Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376 (9757): 2032-2039
    CrossrefPubMedGoogle Scholar
  • 25 Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112 (20) 3080-3087
    CrossrefPubMedGoogle Scholar
  • 26 Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35 (05) 468-477
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Declerck PJ, Moreau H, Jespersen J, Gram J, Kluft C. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 1993; 70 (05) 858-863
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Gram J, Declerck PJ, Sidelmann J, Jespersen J, Kluft C. Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity. Thromb Haemost 1993; 70 (05) 852-857
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Song C, Burgess S, Eicher JD, O'Donnell CJ, Johnson AD. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J Am Heart Assoc 2017; 6 (06) e004918
    CrossrefPubMedGoogle Scholar
  • 30 Dempfle CE, Zips S, Ergül H, Heene DL. Fibrin Assay Comparative Trial study group. The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group. Thromb Haemost 2001; 85 (04) 671-678
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Meijer P, Haverkate F, Kluft C, de Moerloose P, Verbruggen B, Spannagl M. A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost 2006; 95 (03) 567-572
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 2007; 115 (08) 996-1003
    CrossrefPubMedGoogle Scholar
  • 33 Macy EM, Meilahn EN, Declerck PJ, Tracy RP. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med 1993; 117 (01) 67-70
    PubMedGoogle Scholar
  • 34 Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277 (02) 1021-1030
    CrossrefPubMedGoogle Scholar
  • 35 Frère C, Morange PE, Saut N. et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94 (02) 373-379
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Tregouet DA, Schnabel R, Alessi MC. et al; AtheroGene Investigators. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2009; 7 (01) 49-57
    CrossrefPubMedGoogle Scholar
  • 37 Neill EK, Stewart RJ, Schneider MM, Nesheim ME. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2004; 330 (02) 332-341
    CrossrefPubMedGoogle Scholar
  • 38 Heylen E, Van Goethem S, Augustyns K, Hendriks D. Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay. Anal Biochem 2010; 403 (1–2): 114-116
    CrossrefPubMedGoogle Scholar
  • 39 Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26 (02) 423-428
    CrossrefPubMedGoogle Scholar
  • 40 Hendrickx ML, Zatloukalova M, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application. J Thromb Haemost 2014; 12 (02) 229-236
    CrossrefPubMedGoogle Scholar
  • 41 Wyseure T, Rubio M, Denorme F. et al. Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke. Blood 2015; 125 (08) 1325-1332
    CrossrefPubMedGoogle Scholar
  • 42 Willemse JL, Heylen E, Nesheim ME, Hendriks DF. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?. J Thromb Haemost 2009; 7 (12) 1962-1971
    CrossrefPubMedGoogle Scholar
  • 43 Khan SS, Shah SJ, Klyachko E. et al. A null mutation in SERPINE1 protects against biological aging in humans. Sci Adv 2017; 3 (11) o1617
    CrossrefPubMedGoogle Scholar
  • 44 Moore HB, Moore EE, Neal MD. et al. Fibrinolysis shutdown in trauma: historical review and clinical implications. Anesth Analg 2019; 129 (03) 762-773
    CrossrefPubMedGoogle Scholar
  • 45 Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2: 16037
    Google Scholar
  • 46 Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol 2017; 70 (19) 2411-2420
    CrossrefPubMedGoogle Scholar
  • 47 Longstaff C, Adcock D, Olson JD. et al. Harmonisation of D-dimer - a call for action. Thromb Res 2016; 137: 219-220
    CrossrefPubMedGoogle Scholar
  • 48 Jennings I, Woods TA, Kitchen DP, Kitchen S, Walker ID. Laboratory D-dimer measurement: improved agreement between methods through calibration. Thromb Haemost 2007; 98 (05) 1127-1135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Raza I, Davenport R, Rourke C. et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013; 11 (02) 307-314
    CrossrefPubMedGoogle Scholar
  • 50 Gall LS, Brohi K, Davenport RA. Diagnosis and treatment of hyperfibrinolysis in trauma (A European Perspective). Semin Thromb Hemost 2017; 43 (02) 224-234
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Cardenas JC, Matijevic N, Baer LA, Holcomb JB, Cotton BA, Wade CE. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock 2014; 41 (06) 514-521
    CrossrefPubMedGoogle Scholar
  • 52 Chapman MP, Moore EE, Moore HB. et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg 2016; 80 (01) 16-23 ; discussion 23–25
    CrossrefPubMedGoogle Scholar
  • 53 Cotton BA, Faz G, Hatch QM. et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma 2011; 71 (02) 407-414 , discussion 414–417
    CrossrefPubMedGoogle Scholar
  • 54 Neal MD, Moore EE, Walsh M. et al. A comparison between the TEG 6s and TEG 5000 analyzers to assess coagulation in trauma patients. J Trauma Acute Care Surg 2020; 88 (02) 279-285
    CrossrefPubMedGoogle Scholar
  • 55 Ilich A, Bokarev I, Key NS. Global assays of fibrinolysis. Int J Lab Hematol 2017; 39 (05) 441-447
    CrossrefPubMedGoogle Scholar
  • 56 Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89 (02) 228-232
    CrossrefPubMedGoogle Scholar
  • 57 Baksaas-Aasen K, Van Dieren S, Balvers K. et al; TACTIC/INTRN Collaborators. Data-driven development of ROTEM and TEG algorithms for the management of trauma hemorrhage: a prospective observational multicenter study. Ann Surg 2019; 270 (06) 1178-1185
    CrossrefPubMedGoogle Scholar
  • 58 Juffermans NP, Wirtz MR, Balvers K. et al; TACTIC Partners. Towards patient-specific management of trauma hemorrhage: the effect of resuscitation therapy on parameters of thromboelastometry. J Thromb Haemost 2019; 17 (03) 441-448
    CrossrefPubMedGoogle Scholar
  • 59 Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg 2013; 100 (10) 1271-1279
    CrossrefPubMedGoogle Scholar
  • 60 Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I. Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 2018; 391 (10116): 125-132
    CrossrefPubMedGoogle Scholar
  • 61 Roberts I, Shakur H, Afolabi A. et al; CRASH-2 Collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377 (9771): 1096-1101, 1101.e1–1101.e2
    CrossrefPubMedGoogle Scholar
  • 62 Shakur H, Roberts I, Fawole B. et al; WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389 (10084): 2105-2116
    CrossrefPubMedGoogle Scholar
  • 63 CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394 (10210): 1713-1723
    CrossrefPubMedGoogle Scholar
  • 64 Cole E, Davenport R, Willett K, Brohi K. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg 2015; 261 (02) 390-394
    CrossrefPubMedGoogle Scholar
  • 65 Van Haren RM, Valle EJ, Thorson CM. et al. Hypercoagulability and other risk factors in trauma intensive care unit patients with venous thromboembolism. J Trauma Acute Care Surg 2014; 76 (02) 443-449
    CrossrefPubMedGoogle Scholar
  • 66 Collaborators HALT-IT. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395 (10241): 1927-1936
    CrossrefPubMedGoogle Scholar
  • 67 Hunt H, Stanworth S, Curry N. et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2015; 2 (02) CD010438
    PubMedGoogle Scholar
  • 68 Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016; (08) CD007871
    PubMedGoogle Scholar
  • 69 Rugeri L, Levrat A, David JS. et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5 (02) 289-295
    CrossrefPubMedGoogle Scholar
  • 70 Roberts I. Fibrinolytic shutdown: fascinating theory but randomized controlled trial data are needed. Transfusion 2016; 56 (Suppl. 02) S115-S118
    CrossrefPubMedGoogle Scholar
  • 71 Hijazi N, Abu Fanne R, Abramovitch R. et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood 2015; 125 (16) 2558-2567
    CrossrefPubMedGoogle Scholar
  • 72 Longstaff C, Locke M. Increased urokinase and consumption of α2 -antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay. J Thromb Haemost 2019; 17 (01) 195-205
    CrossrefPubMedGoogle Scholar
  • 73 Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med 2020; 48 (09) 1358-1364
    CrossrefPubMedGoogle Scholar
  • 74 Langer F, Kluge S, Klamroth R, Oldenburg J. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie 2020; 40 (03) 264-269
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Klok FA, Kruip MJHA, van der Meer NJM. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 191: 148-150
    CrossrefPubMedGoogle Scholar
  • 76 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1995-2002
    CrossrefPubMedGoogle Scholar
  • 77 Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis 2020; 50 (01) 54-67
    CrossrefPubMedGoogle Scholar
  • 78 Giusti B, Gori AM, Alessi M. et al. Sars-CoV-2 induced coagulopathy and prognosis in hospitalized patients: a snapshot from Italy. Thromb Haemost 2020; 120 (08) 1233-1236
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Zhang L, Yan X, Fan Q. et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18 (06) 1324-1329
    CrossrefPubMedGoogle Scholar
  • 80 Thachil J, Longstaff C, Favaloro EJ, Lippi G, Urano T, Kim PY. SSC Subcommittee on Fibrinolysis of the International Society on Thrombosis and Haemostasis. The need for accurate D-dimer reporting in COVID-19: communication from the ISTH SSC on fibrinolysis. J Thromb Haemost 2020; 18 (09) 2408-2411
    CrossrefPubMedGoogle Scholar
  • 81 Barrett CD, Moore HB, Moore EE. et al. Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review. Res Pract Thromb Haemost 2020; 4 (04) 524-531
    CrossrefPubMedGoogle Scholar
  • 82 Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost 2020; 18 (07) 1548-1555
    CrossrefPubMedGoogle Scholar
  • 83 Longstaff C, Varjú I, Sótonyi P. et al. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem 2013; 288 (10) 6946-6956
    CrossrefPubMedGoogle Scholar
  • 84 Varjú I, Longstaff C, Szabó L. et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost 2015; 113 (06) 1289-1298
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 Weiss E, Roux O, Moyer JD. et al. Fibrinolysis resistance: a potential mechanism underlying COVID-19 coagulopathy. Thromb Haemost 2020; 120 (09) 1343-1345
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Zuo Y, Yalavarthi S, Shi H. et al. Neutrophil extracellular traps in COVID-19. JCI Insight 2020; 5 (11) 138999
    PubMedGoogle Scholar
  • 87 Nougier C, Benoit R, Simon M. et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 2020; 18 (09) 2215-2219
    CrossrefPubMedGoogle Scholar
  • 88 Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274 (08) 5201-5212
    CrossrefPubMedGoogle Scholar
  • 89 Longstaff C, Thelwell C, Williams SC, Silva MM, Szabó L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117 (02) 661-668
    CrossrefPubMedGoogle Scholar
  • 90 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271 (28) 16603-16608
    CrossrefPubMedGoogle Scholar
  • 91 Uitte de Willige S, Standeven KF, Philippou H, Ariëns RA. The pleiotropic role of the fibrinogen gamma' chain in hemostasis. Blood 2009; 114 (19) 3994-4001
    CrossrefPubMedGoogle Scholar
  • 92 Duval C, Allan P, Connell SDA, Ridger VC, Philippou H, Ariëns RAS. Roles of fibrin α- and γ-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost 2014; 111 (05) 842-850
    Article in Thieme ConnectPubMedGoogle Scholar
  • 93 Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through α2-antiplasmin cross-linking. Blood 2011; 117 (23) 6371-6374
    CrossrefPubMedGoogle Scholar
  • 94 Whyte CS, Mitchell JL, Mutch NJ. Platelet-mediated modulation of fibrinolysis. Semin Thromb Hemost 2017; 43 (02) 115-128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Wohner N, Sótonyi P, Machovich R. et al. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol 2011; 31 (10) 2306-2313
    CrossrefPubMedGoogle Scholar
  • 96 Cines DB, Lebedeva T, Nagaswami C. et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 2014; 123 (10) 1596-1603
    CrossrefPubMedGoogle Scholar